$JNCE: Jounce Therapeutics Presents Reverse Translational, Biomarker …

Date: Saturday, November 10th, 2018

Stock(s) mentioned:

Source: Benzinga (https://www.benzinga.com)

Summary: 10, 2018 (GLOBE NEWSWIRE) — Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel …

Full article address: https://www.benzinga.com/pressreleases/18/11/g12675655/jounce-therapeutics-presents-reverse-translational-biomarker-and-precl

Related News:

$JNCE: Jounce Therapeutics, Inc. (JNCE) CEO Richard Murray on Q3 2018 …

$JNCE: Jounce Therapeutics to Present Two Posters from the JTX-2011 …

$JNCE: Jounce Therapeutics Founder Dr. James P. Allison Jointly Awarded …

$JNCE: Jounce Therapeutics to Present at the 2018 Cantor Global …

$JNCE: Jounce Therapeutics to Present Nonclinical Translational Data at …

$JNCE $SGMO $GILD $PFE: Biotech Fire Sale: 2 Top Stocks to Buy Next Week

Latest News:

$HSBA.LN: Huawei CFO Case Hinges on an Offshore Puzzle

$CWH: Why Camping World Holdings Stock Jumped 10% in November

$PNC: 4 Stocks Billionaire Warren Buffett and Insiders Love (and 1 They …

$ZUO $HD $LOW $AMD $AAXN $PFG: AMD, Cisco, Home Depot and Axon: ‘Mad Money’ Lightning Round

$ASNA: Ascena Retail Group Inc (ASNA) CEO David Jaffe on Q1 2019 …

$GERN: Geron Corporation (GERN) CEO John Scarlett Hosts Analyst and …

$VERI: Veritone, Inc. Confirms Receipt of Unsolicited Proposal from Apis …

$ODC: Oil-Dri Corporation of America Appoints New CFO

$B: The global psychologists market was valued at $39.8 billion in 2017

$PCG: PG&E Announces Enhanced Wildfire Prevention and Safety Efforts …

$SEAC: SeaChange International, Inc. (SEAC) CEO Ed Terino on Q3 2019 …